Skip to content
+49 (0) 4102 677 56 14 info@abviris.de
  • Facebook
Search for:
Abviris
  • Company
    • About Us
    • Company Values
    • Quality Management
    • Management Team
    • Career
    • News
    • Events
    • Contact
  • Products
    • Prevo-Check®
  • Science Center
    • HPV and Cancer
    • HPV Cancer Screening
    • High-risk patients
    • Online Courses
    • FAQ
    • Literature
  • Service and Support
    • Regulatory Documents
  • Information for Patients
    • Information for Patients
    • Doctors’ Practices
    • What does HPV mean?
    • Deseases caused by HPV
    • Cancer Screening
  • English
  • Deutsch

News

Abviris Home
/
News

Category: News

Biotech innovator Abviris appoints new leader to drive business expansion
Dec 16, 2020

Biotech innovator Abviris appoints new leader to drive business expansion

NEWS RELEASE Media Contact: Jennie Wilde, Carver Wilde Communications t: +44 (0) 7799 412230/ +44 (0)203 814 8445 e: jennie@carverwilde.com   FOR IMMEDIATE RELEASE   Biotech innovator Abviris appoints new leader to drive business expansion Diagnostics industry expert Dr Roman Niedbal joins as CEO   AHRENSBURG, Germany (December 16, 2020) –Abviris Deutschland GmbH has appointed…

Read More
by Nadine Bong-Schmidtin News0
‘Pinprick’ biomarker blood test offers diagnostic potential in HPV-related cancers
Nov 10, 2020

‘Pinprick’ biomarker blood test offers diagnostic potential in HPV-related cancers

NEWS RELEASE Media Contact: Jennie Wilde, Carver Wilde Communications t: +44 (0) 7799 412230/ +44 (0)203 814 8445 e: jennie@carverwilde.com   FOR IMMEDIATE RELEASE ‘Pinprick’ biomarker blood test offers diagnostic potential in HPV-related cancers Study shows rising antibody levels predict the course of cancer   AHRENSBURG, Germany (November 10, 2020) – A potential breakthrough in…

Read More
by Nadine Bong-Schmidtin News0
AND THE WINNER IS...
Dec 12, 2019

AND THE WINNER IS...

Abviris Deutschland GmbH has been awarded “Pilot of the Year“ by the UK Diagnostics Summit 2019. This prestigious award was presented at the summit on 28 November 2019 in Manchester. High-ranking representatives of the National Health Service (NHS), diagnostics industry and the British IVD Association (BIVDA) honoured the results of a pilot study into the…

Read More
by Nadine Bong-Schmidtin News0
New evidence demonstrates the potential of Prevo-Check® and tumour marker DRH1® for early detection of HPV-induced diseases
Nov 14, 2019

New evidence demonstrates the potential of Prevo-Check® and tumour marker DRH1® for early detection of HPV-induced diseases

Our product Prevo-Check®, a patented test for the detection of HPV16-induced tumours, is the focus of two studies to be presented at the international HPV (human papilloma virus) congress EUROGIN on December 4-7. In a study conducted at the University of Graz, Dr. Weiland and colleagues discovered that Prevo-Check® is a rapid test for identifying…

Read More
by Nadine Bong-Schmidtin News0
Investors Convinced of Potential and Importance of a Novel Cancer Management Concept
Jun 26, 2019

Investors Convinced of Potential and Importance of a Novel Cancer Management Concept

Abviris GmbH Obtains Almost 3 Million Euros in Pre-Series A Financing Abviris GmbH commenced market entry in Germany after successful test-marketing phase (450 customers, 300,000 € revenues) and, respective clinical trials. Initial positioning is targeting screening for HPV induced tumours of head and neck and the anogenital region. Funds raised in round A reveal that…

Read More
by Nadine Bong-Schmidtin News0
Tumour marker for the early detection and therapy of HPV-induced anal cancer for HIV+ patients
May 31, 2019

Tumour marker for the early detection and therapy of HPV-induced anal cancer for HIV+ patients

A pilot study has compared serum samples of HIV+ patients before and after treatment of an HPV induced anal carcinoma using the Prevo-Check®. Prevo-Check® has been confirmed as a high quality test for the early detection and therapy of HPV induced anal cancer for HIV+ patients. Study participants showing a high Prevo-Check® result developed anal…

Read More
by Nadine Bong-Schmidtin News0

Posts navigation

1 2
Company
  • About Us
  • Company Values
  • Quality Management
  • Management Team
  • Career
  • News
  • Events
  • Distributors
  • Contact
Products
  • Prevo-Check®
Science Center
  • HPV and Cancer
  • HPV Cancer Screening
  • High-risk patients
  • Literature
Service and Support
  • Regulatory Documents
Information for Patients
  • Patientenportal
  • Kompetenzpraxen
  • Was bedeutet HPV?
  • Erkrankungen durch HPV
  • Krebsvorsorge
Imprint Privacy
  • AGB
© 2021 Abviris Deutschland. All rights reserved.

Abviris
  • Company
    • About Us
    • Company Values
    • Quality Management
    • Management Team
    • Career
    • News
    • Events
    • Contact
  • Products
    • Prevo-Check®
  • Science Center
    • HPV and Cancer
    • HPV Cancer Screening
    • High-risk patients
    • Online Courses
    • FAQ
    • Literature
  • Service and Support
    • Regulatory Documents
  • Information for Patients
    • Information for Patients
    • Doctors’ Practices
    • What does HPV mean?
    • Deseases caused by HPV
    • Cancer Screening
  • English
  • Deutsch
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkNoPrivacy policy
You can revoke your consent any time using the Revoke consent button.Revoke cookies
Portal für Lieferanten | Nachrichteneingabe (RSS) | Kontakt | Datenschutz | Cookies | Allgemeine Geschäftsbedingunen | Impressum | Bestimmungen